Estimated overall survival according to treatment arms.

(····) MOPP/ABV, 8 cycles (patients at risk, n = 92; deaths, n = 12; 5-year estimate, 85%); () ABVPP, 8 cycles (patients at risk, n = 116; deaths, n = 4; 5-year estimate, 94%); (—·—·) MOPP/ABV, 6 cycles plus RTx (patients at risk, n = 114; deaths, n = 9; 5-year estimate, 88%); (———) ABVPP, 6 cycles plus RTx (patients at risk, n = 96; deaths, n = 17; 5-year estimate, 78%).P = .01.